困难胆管插管对ERCP术后胰腺炎的影响:支架对比吲哚美辛试验数据集的二次分析
该研究为多中心随机对照试验的二次分析,比较直肠吲哚美辛单用与直肠吲哚美辛联合预防性胰管支架置入在高危患者中预防ERCP术后胰腺炎(PEP)的效果。1601例(84.1%)发生困难胆管插管(DBC),平均需12次插管尝试(标准差10)和平均14.7分钟(标准差14.9)。DBC且术前高危者PEP率最高(20.7%),其次为非DBC且术前高危者(13.5%),再次为DBC且术前非高危者(8.8%)。胰管导丝通过次数增加与DBC中PEP相关(aOR 1.97;95%CI 1.25-3.1),吲哚美辛联合胰管支架置入降低DBC中PEP风险(aOR 0.61;95%CI 0.44-0.84),保护效应至少持续至4次胰管导丝通过。
要点
- DBC且术前高危者PEP率为20.7%,高于非DBC且术前高危者的13.5%和DBC且术前非高危者的8.8%。
- DBC中胰管导丝通过次数增加与PEP相关(aOR 1.97;95%CI 1.25-3.1)。
- 吲哚美辛联合胰管支架置入降低DBC中PEP风险(aOR 0.61;95%CI 0.44-0.84),保护效应至少持续至4次胰管导丝通过。
核心结论
- DBC以叠加方式增加术前风险因素之上的PEP风险。
- 胰管导丝通过次数似乎是DBC中增加PEP风险的最主要因素,但吲哚美辛联合胰管支架置入可降低该风险,即使胰管导丝通过次数增加。
研究设计与样本
- 多中心随机对照试验的二次分析,比较直肠吲哚美辛单用与直肠吲哚美辛联合预防性胰管支架置入在高危患者中预防PEP的效果。
- 参与者分为3组:DBC且术前高危、DBC且术前非高危、非DBC且术前高危。
主要发现
- 1601例(84.1%)发生DBC,平均需12次插管尝试(标准差10),平均持续时间14.7分钟(标准差14.9)。
- PEP率在DBC且术前高危组最高(20.7%),其次为非DBC且术前高危组(13.5%),再次为DBC且术前非高危组(8.8%)。
- DBC中胰管导丝通过次数增加与PEP相关(aOR 1.97;95%CI 1.25-3.1),而胰管注射、胰括约肌切开和插管尝试次数与PEP无关。
- DBC中吲哚美辛联合胰管支架置入降低PEP风险(aOR 0.61;95%CI 0.44-0.84),保护效应至少持续至4次胰管导丝通过。
关键数值与推荐
- DBC中胰管导丝通过次数增加与PEP相关(aOR 1.97;95%CI 1.25-3.1)。
- DBC中吲哚美辛联合胰管支架置入降低PEP风险(aOR 0.61;95%CI 0.44-0.84)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Difficult biliary cannulation (DBC) is a known risk factor for developing post-ERCP pancreatitis (PEP). To better understand how DBC increases PEP risk, we examined the interplay between technical aspects of DBC and known PEP risk factors. METHODS: This was a secondary analysis of a multicenter, randomized controlled trial comparing rectal indomethacin alone with the combination of rectal indomethacin and prophylactic pancreatic duct (PD) stent placement for PEP prophylaxis in high-risk patients. Participants were categorized into 3 groups: DBC with high preprocedure risk for PEP, DBC without high preprocedure risk for PEP, and non-DBC at high preprocedure risk for PEP. RESULTS: In all, 1601 participants (84.1%) experienced DBC, which required a mean of 12 cannulation attempts (standard deviation, 10) and mean duration of 14.7 minutes (standard deviation, 14.9). PEP rate was highest (20.7%) in DBC with a high preprocedure risk, followed by non-DBC with a high preprocedure risk (13.5%), and then DBC without a high preprocedure risk (8.8%). Increasing number of PD wire passages (adjusted odds ratio [aOR], 1.97; 95% confidence interval [CI], 1.25-3.1) was associated with PEP in DBC, but PD injection, pancreatic sphincterotomy, and number of cannulation attempts were not associated with PEP. Combining indomethacin with PD stent placement lowered the risk of PEP (aOR, .61; 95% CI, .44-.84) in DBCs. This protective effect was evident in up to at least 4 PD wire passages. CONCLUSIONS: DBC confers higher PEP risk in an additive fashion to preprocedural risk factors. PD wire passages appear to add the greatest PEP risk in DBCs, but combining indomethacin with PD stent placement reduces this risk, even with increasing PD wire passages.
引用
- Han S, Zhang J, Durkalski-Mauldin V, et al. Impact of difficult biliary cannulation on post-ERCP pancreatitis: secondary analysis of the stent versus indomethacin trial dataset. Gastrointest Endosc. 2024. PMID: 39389431. doi:10.1016/j.gie.2024.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。